rbc capital - Search News

FMC downgraded at RBC Capital

FMC downgraded at RBC Capital; shares plunge on weak outlook

FMC (NYSE:FMC) on Wednesday was downgraded to Sector Perform from a previous investment rating of Outperform by analysts at RBC Capital Markets. They said the maker of insecticides and other farming chemicals faces weak demand,

Hosted on MSN · 4h

RBC Capital Downgrades FMC (FMC)

Fintel reports that on February 5, 2025, RBC Capital downgraded their outlook for FMC (NYSE:FMC) from Outperform to Sector Perform. Analyst Price Forecast Suggests 89.64% Upside As of January 30, 2025,

Business Insider · 1d

FMC downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital analyst Arun Viswanathan downgraded FMC (FMC) to Sector Perform from Outperform with a price target of $47, down from $78. When

Investing.com on MSN · 23h

FMC stock rating cut to Sector Perform by RBC Capital

RBC Capital issued a downgrade for FMC Corp . (NYSE:FMC) from Outperform to Sector Perform, significantly reducing the price target to $47.00 from the previous $78.00. The decision came after FMC's fourth-quarter earnings report,

Hosted on MSN4h

RBC Capital Upgrades SSR Mining (SSRM)

Fintel reports that on February 5, 2025, RBC Capital upgraded their outlook for SSR Mining (NasdaqGS:SSRM) from Underperform ...

RBC Capital Remains a Buy on DCC plc (DCC)

RBC Capital analyst Andrew Brooke maintained a Buy rating on DCC plc (DCC – Research Report) yesterday and set a price target of p6,000.00. The ...

bovnews19h

Why Did RBC Capital Mkts Give SAGE Therapeutics Inc (SAGE) Stock Sector Perform Rating?

RBC Capital Mkts has recently raised SAGE Therapeutics Inc (SAGE) stock to Sector Perform rating, as announced on November 21, 2024, according to Finviz. Earlier, on October 10, 2 ...

12hon MSN

Energy & Utilities Roundup: Market Talk

Find insight on TotalEnergies, oil and natural gas futures, and more in the latest Market Talks covering Energy and Utilities ...

RBC Capital Reaffirms Their Buy Rating on Moody’s (MCO)

RBC Capital analyst Ashish Sabadra maintained a Buy rating on Moody’s (MCO – Research Report) on February 4 and set a price target of $550.00.

Sarepta could be down on patient death in FDA database, says RBC Capital

RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results